ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia
Ownership
-
Employees
-
Market Cap
-
Website

A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema

Phase 3
Completed
Conditions
Interventions
First Posted Date
2005-09-15
Last Posted Date
2014-08-04
Lead Sponsor
Allergan
Target Recruit Count
494
Registration Number
NCT00168389

Safety and Efficacy of Brimonidine in Patients With Glaucoma or Ocular Hypertension

Phase 3
Completed
Conditions
First Posted Date
2005-09-15
Last Posted Date
2011-05-30
Lead Sponsor
Allergan
Target Recruit Count
207
Registration Number
NCT00168363

A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches

First Posted Date
2005-09-12
Last Posted Date
2013-11-18
Lead Sponsor
Allergan
Target Recruit Count
679
Registration Number
NCT00156910

A Phase 3 Study to Compare the Safety and Efficacy of 5% Dapsone Topical Gel, (DTG) Twice Daily in Combination With Once Daily Vehicle Control, Adapalene Gel 0.1% or Benzoyl Peroxide Gel 4%

Phase 3
Completed
Conditions
First Posted Date
2005-09-09
Last Posted Date
2011-05-30
Lead Sponsor
Allergan
Target Recruit Count
301
Registration Number
NCT00151541

Evaluation of Eflornithine on Facial and Forearm Skin

Phase 4
Completed
Conditions
First Posted Date
2005-09-09
Last Posted Date
2019-10-30
Lead Sponsor
Allergan
Target Recruit Count
78
Registration Number
NCT00152048

Memantine in Patients With Chronic Glaucoma

Phase 3
Completed
Conditions
First Posted Date
2005-09-02
Last Posted Date
2010-11-04
Lead Sponsor
Allergan
Target Recruit Count
1119
Registration Number
NCT00141882

Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function

First Posted Date
2004-02-26
Last Posted Date
2011-10-03
Lead Sponsor
Allergan
Target Recruit Count
155
Registration Number
NCT00076687

Research Study in Patients With Persistent Macular Edema

First Posted Date
2002-05-07
Last Posted Date
2011-05-30
Lead Sponsor
Allergan
Target Recruit Count
315
Registration Number
NCT00035906
Locations
🇺🇸

Oculex Pharmaceuticals, Sunnyvale, California, United States

Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome

First Posted Date
2001-10-29
Last Posted Date
2011-05-30
Lead Sponsor
Allergan
Target Recruit Count
290
Registration Number
NCT00025818
Locations
🇺🇸

UCLA, Los Angeles, California, United States

🇺🇸

Indiana University, Indianapolis, Indiana, United States

🇺🇸

Eyecare of La Jolla, La Jolla, California, United States

and more 14 locations
© Copyright 2024. All Rights Reserved by MedPath